Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904302 | 0.94 | HIF1A (0.38) | HIF1AMEN1KMT2AMKNK2EIF4E | |
| SCHEMBL4900430 | 0.89 | KDM4E (0.41) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL4575589 | 0.88 | HRH1 (0.39) | KDM4EHIF1AMEN1KMT2ABRPF1 | |
| SCHEMBL4935908 | 0.88 | KDM4E (0.42) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL4898152 | 0.88 | KDM4E (0.42) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL4906366 | 0.87 | KDM4E (0.44) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL4898690 | 0.86 | CNR2 (0.40) | KDM4E | |
| SCHEMBL4906293 | 0.85 | KDM4E (0.48) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL4909162 | 0.84 | KDM4E (0.43) | KDM4EHIF1AMEN1KMT2AMAPK14 | |
| SCHEMBL16021049 | 0.84 | GRIN2B (0.41) | KDM4EHIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | KDM4E 1139/4885HIF1A 3129/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.